Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) EBIT: 2023-2024

Historic EBIT for Artiva Biotherapeutics (ARTV) over the last 2 years, with Dec 2024 value amounting to -$67.3 million.

  • Artiva Biotherapeutics' EBIT fell 52.61% to -$18.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$67.3 million, marking a year-over-year change of. This contributed to the annual value of -$67.3 million for FY2024, which is 119.37% down from last year.
  • According to the latest figures from FY2024, Artiva Biotherapeutics' EBIT is -$67.3 million, which was down 119.37% from -$30.7 million recorded in FY2023.
  • Artiva Biotherapeutics' 5-year EBIT high stood at -$30.7 million for FY2023, and its period low was -$67.3 million during FY2024.
  • For the 2-year period, Artiva Biotherapeutics' EBIT averaged around -$49.0 million, with its median value being -$49.0 million (2023).
  • Data for Artiva Biotherapeutics' EBIT shows a maximum YoY slumped of 119.37% (in 2024) over the last 5 years.
  • Over the past 2 years, Artiva Biotherapeutics' EBIT (Yearly) stood at -$30.7 million in 2023, then crashed by 119.37% to -$67.3 million in 2024.